Growth hormone-resistant syndromes: long-term follow-up

Area of Science:

• Pediatric Endocrinology
• Growth Hormone Therapy
• Metabolic Disorders

Background:

• Recombinant human insulin-like growth factor-I (rhIGF-I) is an approved therapeutic for short stature.
• Clinical trials evaluated rhIGF-I for over a decade.
• Initial use targeted children with primary IGF-I deficiency, including those with growth hormone (GH) receptor defects or GH antibodies.

Purpose of the Study:

• To assess the long-term efficacy and safety of rhIGF-I in treating short stature.
• To compare rhIGF-I treatment outcomes with human growth hormone (hGH) therapy.

Main Methods:

• Long-term clinical trials involving children with primary IGF-I deficiency.
• Administration of rhIGF-I to eligible pediatric patients.
• Monitoring of growth rates and adult height achievement.

Main Results:

• Sustained improvements in growth rate observed over many years with rhIGF-I treatment.
• rhIGF-I therapy appears to enhance adult height.
• Growth outcomes with rhIGF-I are not as robust as those achieved with hGH in GH-deficient children.
• Common side effects were manageable and rarely led to treatment discontinuation.

Conclusions:

• rhIGF-I is an effective treatment for improving growth in children with primary IGF-I deficiency.
• Long-term rhIGF-I therapy can improve adult height, though hGH may yield more significant results in specific cases.
• The safety profile of rhIGF-I is generally favorable, with manageable side effects.